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Statement of translational relevance
An important factor for optimal cancer treatment is correct tumor classification. In the present investigation we define five molecular subtypes of bladder cancer that show significant differences in prognosis. The suggested subtypes are defined by distinct gene expression signatures specific for cell cycle, cytokeratins, cell adhesion, receptor tyrosine kinases, and immune response. The class-defining gene signatures show coordinated expression irrespective of pathological stage and grade, indicating the molecular subtypes as intrinsic properties of the tumors. Hence, our proposed molecular stratification adds valuable additional information to current pathological staging and grading. A systematic analysis revealed that specific drug target profiles were associated with individual subtypes. We anticipate that the suggested molecular classification will be valuable in future evaluations of urothelial carcinoma and help to define clinicogenomic subtypes of importance for new therapeutic strategies.
Introduction
Bladder cancer is the fourth most common tumor type among males. More than 90% of bladder cancers are urothelial cell carcinoma (UC) and about 5% are squamous cell carcinoma (SCC). The gender ratio of male to female is 3 to 1 and the best known environmental risk factor is smoking. UC patients are stratified by pathological stage and grade; the basis of clinical decision-making. The stage classification differentiates between non-muscle invasive (NMI) (Tis, Ta, and T1) and muscle-invasive tumors (MI) (T2, T3 and T4) according to the invasion depth. Ta tumors are restricted to the urothelium, T1 tumors have invaded the lamina propria, and T2, T3, and T4 tumors have invaded the superficial muscle, perivesical fat, and surrounding organs, respectively. Tis is poorly understood and believed to be a precursor of MI tumors. The majority of patients, 70%, initially present with NMI tumors, however, up to 70% of these develop local recurrences, and patients may frequently have recurrences.
Roughly 25% of NMI patients progress to MI disease with a potential to develop metastasis.
One problem in day-to-day clinical practice is that pathological assessment is reported to be fairly uncertain (1) (2) (3) . Accordingly, there have been efforts to complement the pathological evaluation with biomarkers that can be judged in a more objective manner (4) (5) (6) . A further extension of this approach would be to base a tumor classification system primarily on molecular features, integrating molecular data from several biological levels. An advantage of such an approach would be that a more comprehensive description of existing tumor subtypes could be attained. One method is to apply gene expression data to stratify tumors based on molecular phenotypes. Only a limited number of high-throughput gene expression analyses of bladder cancer have, however, been performed (7) (8) (9) (10) (11) (12) and the main focus has been on the identification of gene signatures with possible prognostic values. For example Kim et al. (12) described a gene profile for progression as well as for response to BCG treatment, SanchezCarbayo et al. (8) and Blaveri et al. (9) reported gene profiles for tumor staging and disease-specific survival, and Dyrskjot et al. (10) have reported profiles for staging, recurrence, and progression. Very little has been done, though, to use expression data to investigate the existence of inherent molecular subtypes that may complement current histopathological classification systems. Such a molecular classification system has been developed for, e.g., breast cancer in which four main classes of tumors have been defined; Luminal A, Luminal B, HER2-enriched, and Basal-like, which show different clinical outcomes (13, 14) . In a recent study, we defined two molecular subtypes of UC governed by distinct biological processes and mutation profiles (11) . In the present investigation, we have extended the molecular classification of UC in a much more comprehensive analysis of 308 tumors allowing the definition of five major molecular subtypes of UC; Urobasal A, Genomically unstable, Urobasal B, SCC-like, and a heterogeneous infiltrated class of tumors. These subtypes show distinct molecular profiles, differ in survival rates, and can be validated in publicly available data. They furthermore cut across pathological staging and grading and may thus add valuable additional molecular information to pathological classification.
Materials and Methods

Tumor Samples
Urothelial carcinomas were collected by cold-cup biopsies from the exophytic part of the bladder tumor in 308 patients undergoing transurethral resection at hospitals of the Swedish southern healthcare region. Informed consent was obtained from all patients and the study was approved by the Local Ethical Committee of Lund University. Detailed pathological and clinical data is given in Table S1, and summarized in table S2 .
RNA extraction, labeling and hybridization, preprocessing of expression data
Tumor samples were thawed in RNAlater ICE (Ambion), disrupted and homogenized using TissueLyser (Qiagen) and Qiashredder (Qiagen), and RNA extracted using Allprep or RNeasy kits (Qiagen). RNA quality was assessed on Agilent 2100 Bioanalyzer (Agilent). Labeling and hybridization to Direct Hyb HT-12 V3 beadarrays (Illumina) were performed by the SCIBLU facility at Lund University (http://www.lth.se/sciblu). Preprocessing and quality control steps are described in detail in Text S1. A 50% intensity filter followed by merging of probes for the same gene resulted in 13 953 genes used for supervised analyses. For unsupervised analysis a further 50% variance filter was applied. Raw and processed data, together with sample annotations, are deposited at the Gene Expression Omnibus (GSE32894).
Statistical analyses
Molecular subtypes were identified through a step-wise procedure using hierarchical clustering analyses (HCA) of bootstrapped datasets as described in Text S1. For validation, the same procedure was applied to data sets of Stransky et al. (7) Sanchez-Carbayo et al. (8) and Kim et al., (12) (Text S1). Quality threshold clusters (QTCs) were defined by a minimum correlation of 0.5 and a minimum of 20 genes for each cluster (15) . Sample classification was performed in a leave-one-out cross validation loop using ANOVA or t-test as feature selection method, and nearest centroid classification (NCC) as classification algorithm (16) . When applied to independent data the classifier was built using all 308 cases. Statistical analyses were performed using R 2.9.2 (http://www.r-project.org) and TMEV (17) . 
Tissue microarrays and immunohistochemistry
Results
Defining UC molecular subtypes
Hierarchical cluster analysis of the 308 samples indicated the presence of several tumor clusters. To firmly establish these results we used a successive two-group split approach (Text S1). The first split grouped the tumors into MS1 and MS2 subtypes described by us previously (11) . MS1 and MS2 tumors were then treated individually to establish further divisions, each division being subjected to several quality tests. This procedure was repeated resulting in a total of seven tumor clusters ( Figure 1 ). We then performed an ANOVA based on 13 953 genes and used the seven clusters as grouping variable; a total of 8 377 genes showed a significant association with molecular subtype. This shows that a large proportion of the assayed genes are in fact associated with the identified tumor clusters. The overall structure of the tumor classification was corroborated in three external data sets using an identical unsupervised bootstrap analysis and organization into molecular subtypes (Text S1, Figure S1 ). We then derived Nearest Centroid Classification (NCC) classifiers using two different feature selection methods, resulting in a classification accuracy of 91% in both cases (LOOCV), and when applied to the independent Kim data an accuracy of 81% (Text S1).
Based on the above results we conclude that UC may be robustly classified into at least seven distinct gene expression clusters.
Biological characterization of UC molecular subtypes
To reveal biological themes specific for the tumor clusters we examined groups of genes with coordinated expression as well as genes selected based on their biological functions. We also investigated subtype-specific distribution of mutations in the FGFR3, PIK3CA, and TP53 genes. Below we summarize key differences between the subtypes exemplified in Figure Urobasal A tumors also showed a higher PIK3CA mutation frequency compared to MS2a (25% vs. 8%, p<0.002, Chi-2), whereas the frequency of TP53 mutations was significantly higher in MS2a (48% vs. 11%, p<0.0001, Chi-2). This identifies the Urobasal A as FGFR3
and PIK3CA mutated, and MS2a as TP53 mutated. The strong association between TP53 and the MS2a tumor cluster, and the fact that these tumors show grossly rearranged genomes (11) prompted us the rename this group to Genomically unstable. FGFR3 and PIK3CA mutation frequencies in MS2b2.1 did not differ from the Urobasal A subtype (p>0.25, Chi-2), and 
UC molecular subtypes are independent of pathological stratification
The defined molecular subtypes do not overlap with pathological stratification ( Figure 5 ).
Even though Ta tumors are dominated by the Urobasal A subtype, T1 tumors are composed of Urobasal A and Genomically unstable cases, and MI cases may be of any subtype. Low grade tumors, G1 and G2, are predominantly of the Urobasal A subtype whereas G3 tumors may be of any subtype ( Figure 5B ). Finally, when limiting the analysis to non-muscle invasive high grade tumors (T1G3) it may be concluded that these are very heterogeneous at the molecular level ( Figure 5C ). Hence, the molecular subtypes differentiate the tumors within each pathological entity further and add additional information for tumor classification. We 
UC molecular subtypes differ in expression of possible drug targets
We downloaded potential drug targets from the Drugbank database (18) targets. This resulted in 46 compound-target pairs of which 37 showed subtype-specific expression in the current data set. In Figure 2 we show a heat map of a selected number of drug target genes (see Text S2 for all target genes). Importantly, gene expression of potential drug targets was associated with molecular subtype rather than with pathological stratification, as exemplified by the targets for tipifarnib and valrubicin, both tested in clinical trials for UC.
( Figure 6 ) (19, 20) .
Discussion
We performed an extensive gene expression study of UC particularly aimed at defining molecular subtypes of bladder cancer with the belief that such subtypes may be objectively assessed, biologically relevant, and function as a complement to the current pathological classification. In a first step we used robust statistical methods to arrive at well separated groups of tumors. Independently, we applied the same strategy to three previously published bladder cancer data sets, and could thus validate the overall structure of the tumor subtypes in independent data. We investigated the biological significance of the subtypes by identifying co-expressed genes as well as the expression patterns of selected genes. Using this approach we identified five major subtypes of UC with distinct biological and clinical properties; The Genomically unstable subtype was characterized by frequent TP53 mutations, CCNE and ERBB2 expression, and low cytokeratin expression. Genomically unstable cases represent a high risk group as close to 40% were muscle invasive. This subtype also showed low PTEN expression and thus coincides with the high risk UC described by Puzio-Kuter et al. (25) (Text S2). Several genes previously associated with tumor progression, recurrence, or positive cytology, were found to be up-regulated within the Genomically unstable group, e.g., KPNA2, (26) , HMOX1 (27) , and CTSL1 and CTSL2 (28) . It would thus be expected that a large fraction of the genes associated with this subtype would show prognostic values with similar magnitudes to the reported ones. A major difference between the Urobasal A and the Genomically unstable subtype was that the latter showed increased activity of late G1 phase, CCNE, and late cell cycle genes e.g., CCNA, CCNB, and CDC20. Expression of target genes for tipifarnib (FNTA) and valrubicin (TOP2A) is shown. Red, high expression; green, low expression; gray fields, insufficient data.
